GlassScriptPhysician profile
John R Shipp
NPI 1538379789
$10,072.35
in general payments reported to CMS, 2019-2025
26 companies · $595 in 2025
The $595 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $481 · 2020: $473 · 2021: $547 · 2022: $6,541 · 2023: $791 · 2024: $644 · 2025: $595.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,005 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,004.79 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $6,052.22 | 2022-2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Injector Handpiece |
| Alcon Vision LLC | $1,039.93 | 2019-2025 | Clareon, Hydrus Microstent, Argos |
| Mallinckrodt Hospital Products INC. | $536.57 | 2022-2025 | Acthar |
| Sight Sciences, INC. | $312.34 | 2019-2024 | Omni Surgical System |
| Abbvie INC. | $296.34 | 2022-2025 | Durysta, Xen Glaucoma Treatment System |
| Johnson & Johnson Surgical Vision, INC. | $288.36 | 2019-2021 | |
| Ocular Therapeutix, INC. | $252.06 | 2020-2025 | Dextenza |
| Eyepoint US, INC. | $217.29 | 2019-2020 | |
| Ivantis, INC | $176.18 | 2020-2021 | |
| Amgen INC. | $126.72 | 2024-2025 | Tepezza |
| Allergan, INC. | $123.60 | 2019-2021 | |
| Oyster Point Pharma, INC. | $65.23 | 2022-2025 | Ryzumvi, Tyrvaya |
| Iridex Corporation | $61.99 | 2021-2022 | |
| Bausch & Lomb Americas INC. | $60.69 | 2023-2025 | Vyzulta, Miebo, Xiidra |
| Biotissue Holdings INC. | $57.36 | 2020-2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rayner Intraocular Lenses Limited | $55.42 | 2022 | |
| Harrow Eye, LLC | $53.37 | 2023-2024 | Iheezo, Vevye |
| Omeros Corporation | $50.64 | 2019-2021 | |
| Horizon Therapeutics Plc | $43.82 | 2023 | |
| Glaukos Corporation | $41.10 | 2025 | Idosetr |
| Ani Pharmaceuticals, INC. | $39.16 | 2025 | Yutiq, Purified Cortrophin Gel |
| New World Medical,INC. | $37.35 | 2023-2025 | Via360, Streamline, Ahmed Glaucoma Valve |
| Sun Pharmaceutical Industries INC. | $28.02 | 2019-2021 | |
| Dompe US, INC. | $20.07 | 2021 | |
| Carl Zeiss Meditec USA, INC. | $18.31 | 2025 | Cirrus Hd-Oct |
| Eyevance Pharmaceuticals LLC | $18.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Shipp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.